Loading…

Chemical shift assignments and secondary structure of the surrogate domain for drug discovery studies of human heparanase

Heparanase is an endoglycosidase that specifically degrades heparan sulfate, one of the main components of the extracellular matrix. Heparanase is implicated in cancer processes such as tumour formation, angiogenesis and metastasis, making it a very attractive target in drug discovery. Its active fo...

Full description

Saved in:
Bibliographic Details
Published in:Biomolecular NMR assignments 2015-04, Vol.9 (1), p.15-19
Main Authors: Mosulén, Silvia, Pineda-Lucena, Antonio, Carbajo, Rodrigo J.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c394t-20d79a5ec4c0f8e19f943fbf62267908316b8c9af351716e2f8036ec857278493
container_end_page 19
container_issue 1
container_start_page 15
container_title Biomolecular NMR assignments
container_volume 9
creator Mosulén, Silvia
Pineda-Lucena, Antonio
Carbajo, Rodrigo J.
description Heparanase is an endoglycosidase that specifically degrades heparan sulfate, one of the main components of the extracellular matrix. Heparanase is implicated in cancer processes such as tumour formation, angiogenesis and metastasis, making it a very attractive target in drug discovery. Its active form is a heterodimer constituted by a 45 kDa glycosylated subunit (Lys158–Ile543) non-covalently bound to a smaller 8 kDa polypeptide (Gln36–Glu109). Residues Glu225 and Glu343 are critical in its catalytic mechanism and two heparan sulfate binding sites (Lys158–Asp171 and Gln270–Lys280) have been identified in the enzyme. Here we report the 1 H, 13 C and 15 N chemical shift assignments, secondary structure and chemical shift deviations from random coil of the domain of human heparanase comprising residues Lys158–Lys417, a construct that has been validated as surrogate of the full length protein in the search of novel inhibitors for this enzyme.
doi_str_mv 10.1007/s12104-013-9536-9
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1661333591</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3615679541</sourcerecordid><originalsourceid>FETCH-LOGICAL-c394t-20d79a5ec4c0f8e19f943fbf62267908316b8c9af351716e2f8036ec857278493</originalsourceid><addsrcrecordid>eNp1kU2LFDEQhoMo7rr6A7xIwIuX1lTSnY-jDOsHLHhR8NZk0pXpXqaTMdUR9t_b7ayLCJ4SyPO-Keph7CWItyCEeUcgQbSNANW4TunGPWKXYE3bSCO-P364g71gz4huhdBSSHjKLmSrXAedvmR3uxHnKfgjp3GKC_dE0yHNmBbiPg2cMOQ0-HLHaSk1LLUgz5EvI3KqpeSDX5APefZT4jEXPpR64MNEIf_E36E6TEhbZKyzT3zEky8-ecLn7En0R8IX9-cV-_bh-uvuU3Pz5ePn3fubJijXLo0Ug3G-w9AGES2Ci65VcR-1lNo4YRXovQ3OR9WBAY0yWqE0BtsZaWzr1BV7c-49lfyjIi39vI6Hx6NPmCv1oDUopToHK_r6H_Q215LW6TZKWGuc2QrhTIWSiQrG_lSmeV1RD6LfvPRnL_3qpd-89Fvm1X1z3c84PCT-iFgBeQZofUoHLH99_d_WXy-nmT4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1660887979</pqid></control><display><type>article</type><title>Chemical shift assignments and secondary structure of the surrogate domain for drug discovery studies of human heparanase</title><source>Springer Nature</source><creator>Mosulén, Silvia ; Pineda-Lucena, Antonio ; Carbajo, Rodrigo J.</creator><creatorcontrib>Mosulén, Silvia ; Pineda-Lucena, Antonio ; Carbajo, Rodrigo J.</creatorcontrib><description>Heparanase is an endoglycosidase that specifically degrades heparan sulfate, one of the main components of the extracellular matrix. Heparanase is implicated in cancer processes such as tumour formation, angiogenesis and metastasis, making it a very attractive target in drug discovery. Its active form is a heterodimer constituted by a 45 kDa glycosylated subunit (Lys158–Ile543) non-covalently bound to a smaller 8 kDa polypeptide (Gln36–Glu109). Residues Glu225 and Glu343 are critical in its catalytic mechanism and two heparan sulfate binding sites (Lys158–Asp171 and Gln270–Lys280) have been identified in the enzyme. Here we report the 1 H, 13 C and 15 N chemical shift assignments, secondary structure and chemical shift deviations from random coil of the domain of human heparanase comprising residues Lys158–Lys417, a construct that has been validated as surrogate of the full length protein in the search of novel inhibitors for this enzyme.</description><identifier>ISSN: 1874-2718</identifier><identifier>EISSN: 1874-270X</identifier><identifier>DOI: 10.1007/s12104-013-9536-9</identifier><identifier>PMID: 24395156</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Amino Acid Sequence ; Biochemistry ; Biological and Medical Physics ; Biophysics ; Cancer ; Drug Discovery ; Enzyme Inhibitors - pharmacology ; Glucuronidase - antagonists &amp; inhibitors ; Glucuronidase - chemistry ; Heparan sulfate ; Humans ; Matrix ; Molecular Sequence Data ; NMR ; Nuclear magnetic resonance ; Nuclear Magnetic Resonance, Biomolecular ; Physics ; Physics and Astronomy ; Polymer Sciences ; Protein Structure, Secondary ; Protein Structure, Tertiary</subject><ispartof>Biomolecular NMR assignments, 2015-04, Vol.9 (1), p.15-19</ispartof><rights>Springer Science+Business Media Dordrecht 2014</rights><rights>Springer Science+Business Media Dordrecht 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c394t-20d79a5ec4c0f8e19f943fbf62267908316b8c9af351716e2f8036ec857278493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24395156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mosulén, Silvia</creatorcontrib><creatorcontrib>Pineda-Lucena, Antonio</creatorcontrib><creatorcontrib>Carbajo, Rodrigo J.</creatorcontrib><title>Chemical shift assignments and secondary structure of the surrogate domain for drug discovery studies of human heparanase</title><title>Biomolecular NMR assignments</title><addtitle>Biomol NMR Assign</addtitle><addtitle>Biomol NMR Assign</addtitle><description>Heparanase is an endoglycosidase that specifically degrades heparan sulfate, one of the main components of the extracellular matrix. Heparanase is implicated in cancer processes such as tumour formation, angiogenesis and metastasis, making it a very attractive target in drug discovery. Its active form is a heterodimer constituted by a 45 kDa glycosylated subunit (Lys158–Ile543) non-covalently bound to a smaller 8 kDa polypeptide (Gln36–Glu109). Residues Glu225 and Glu343 are critical in its catalytic mechanism and two heparan sulfate binding sites (Lys158–Asp171 and Gln270–Lys280) have been identified in the enzyme. Here we report the 1 H, 13 C and 15 N chemical shift assignments, secondary structure and chemical shift deviations from random coil of the domain of human heparanase comprising residues Lys158–Lys417, a construct that has been validated as surrogate of the full length protein in the search of novel inhibitors for this enzyme.</description><subject>Amino Acid Sequence</subject><subject>Biochemistry</subject><subject>Biological and Medical Physics</subject><subject>Biophysics</subject><subject>Cancer</subject><subject>Drug Discovery</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Glucuronidase - antagonists &amp; inhibitors</subject><subject>Glucuronidase - chemistry</subject><subject>Heparan sulfate</subject><subject>Humans</subject><subject>Matrix</subject><subject>Molecular Sequence Data</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Nuclear Magnetic Resonance, Biomolecular</subject><subject>Physics</subject><subject>Physics and Astronomy</subject><subject>Polymer Sciences</subject><subject>Protein Structure, Secondary</subject><subject>Protein Structure, Tertiary</subject><issn>1874-2718</issn><issn>1874-270X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp1kU2LFDEQhoMo7rr6A7xIwIuX1lTSnY-jDOsHLHhR8NZk0pXpXqaTMdUR9t_b7ayLCJ4SyPO-Keph7CWItyCEeUcgQbSNANW4TunGPWKXYE3bSCO-P364g71gz4huhdBSSHjKLmSrXAedvmR3uxHnKfgjp3GKC_dE0yHNmBbiPg2cMOQ0-HLHaSk1LLUgz5EvI3KqpeSDX5APefZT4jEXPpR64MNEIf_E36E6TEhbZKyzT3zEky8-ecLn7En0R8IX9-cV-_bh-uvuU3Pz5ePn3fubJijXLo0Ug3G-w9AGES2Ci65VcR-1lNo4YRXovQ3OR9WBAY0yWqE0BtsZaWzr1BV7c-49lfyjIi39vI6Hx6NPmCv1oDUopToHK_r6H_Q215LW6TZKWGuc2QrhTIWSiQrG_lSmeV1RD6LfvPRnL_3qpd-89Fvm1X1z3c84PCT-iFgBeQZofUoHLH99_d_WXy-nmT4</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Mosulén, Silvia</creator><creator>Pineda-Lucena, Antonio</creator><creator>Carbajo, Rodrigo J.</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20150401</creationdate><title>Chemical shift assignments and secondary structure of the surrogate domain for drug discovery studies of human heparanase</title><author>Mosulén, Silvia ; Pineda-Lucena, Antonio ; Carbajo, Rodrigo J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c394t-20d79a5ec4c0f8e19f943fbf62267908316b8c9af351716e2f8036ec857278493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Amino Acid Sequence</topic><topic>Biochemistry</topic><topic>Biological and Medical Physics</topic><topic>Biophysics</topic><topic>Cancer</topic><topic>Drug Discovery</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Glucuronidase - antagonists &amp; inhibitors</topic><topic>Glucuronidase - chemistry</topic><topic>Heparan sulfate</topic><topic>Humans</topic><topic>Matrix</topic><topic>Molecular Sequence Data</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Nuclear Magnetic Resonance, Biomolecular</topic><topic>Physics</topic><topic>Physics and Astronomy</topic><topic>Polymer Sciences</topic><topic>Protein Structure, Secondary</topic><topic>Protein Structure, Tertiary</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mosulén, Silvia</creatorcontrib><creatorcontrib>Pineda-Lucena, Antonio</creatorcontrib><creatorcontrib>Carbajo, Rodrigo J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Biomolecular NMR assignments</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mosulén, Silvia</au><au>Pineda-Lucena, Antonio</au><au>Carbajo, Rodrigo J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chemical shift assignments and secondary structure of the surrogate domain for drug discovery studies of human heparanase</atitle><jtitle>Biomolecular NMR assignments</jtitle><stitle>Biomol NMR Assign</stitle><addtitle>Biomol NMR Assign</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>9</volume><issue>1</issue><spage>15</spage><epage>19</epage><pages>15-19</pages><issn>1874-2718</issn><eissn>1874-270X</eissn><abstract>Heparanase is an endoglycosidase that specifically degrades heparan sulfate, one of the main components of the extracellular matrix. Heparanase is implicated in cancer processes such as tumour formation, angiogenesis and metastasis, making it a very attractive target in drug discovery. Its active form is a heterodimer constituted by a 45 kDa glycosylated subunit (Lys158–Ile543) non-covalently bound to a smaller 8 kDa polypeptide (Gln36–Glu109). Residues Glu225 and Glu343 are critical in its catalytic mechanism and two heparan sulfate binding sites (Lys158–Asp171 and Gln270–Lys280) have been identified in the enzyme. Here we report the 1 H, 13 C and 15 N chemical shift assignments, secondary structure and chemical shift deviations from random coil of the domain of human heparanase comprising residues Lys158–Lys417, a construct that has been validated as surrogate of the full length protein in the search of novel inhibitors for this enzyme.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>24395156</pmid><doi>10.1007/s12104-013-9536-9</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1874-2718
ispartof Biomolecular NMR assignments, 2015-04, Vol.9 (1), p.15-19
issn 1874-2718
1874-270X
language eng
recordid cdi_proquest_miscellaneous_1661333591
source Springer Nature
subjects Amino Acid Sequence
Biochemistry
Biological and Medical Physics
Biophysics
Cancer
Drug Discovery
Enzyme Inhibitors - pharmacology
Glucuronidase - antagonists & inhibitors
Glucuronidase - chemistry
Heparan sulfate
Humans
Matrix
Molecular Sequence Data
NMR
Nuclear magnetic resonance
Nuclear Magnetic Resonance, Biomolecular
Physics
Physics and Astronomy
Polymer Sciences
Protein Structure, Secondary
Protein Structure, Tertiary
title Chemical shift assignments and secondary structure of the surrogate domain for drug discovery studies of human heparanase
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T14%3A02%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chemical%20shift%20assignments%20and%20secondary%20structure%20of%20the%20surrogate%20domain%20for%20drug%20discovery%20studies%20of%20human%20heparanase&rft.jtitle=Biomolecular%20NMR%20assignments&rft.au=Mosul%C3%A9n,%20Silvia&rft.date=2015-04-01&rft.volume=9&rft.issue=1&rft.spage=15&rft.epage=19&rft.pages=15-19&rft.issn=1874-2718&rft.eissn=1874-270X&rft_id=info:doi/10.1007/s12104-013-9536-9&rft_dat=%3Cproquest_cross%3E3615679541%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c394t-20d79a5ec4c0f8e19f943fbf62267908316b8c9af351716e2f8036ec857278493%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1660887979&rft_id=info:pmid/24395156&rfr_iscdi=true